Vamorolone is a first-in-class drug that borrows some activities of corticosteroids (anti-inflammatory activity via NFkB repression), while adding new activities not seen with corticosteroids (eplerenone-like activity; membrane stabilization activity). Vamorolone hopes to retain the beneficial anti-inflammatory and muscle strengthening aspects of corticosteroids, while decreasing some of the undesirable side effects (bone fragility, stunted growth, insulin resistance, mood changes, delay of puberty and others). Vamorolone is given as an oral liquid flavored formulation at home daily.
A Phase 2a clinical trial is completed and data is currently under interpretation. A Phase 2a extension clinical trial of the same patients is fully enrolled and ongoing. A Long Term Extension study is open for the same patients, and is ongoing. Results from these phase 2a studies have been published.
A Phase 2b/3 clinical trial is currently recruiting.
On March 23, 2020, ReveraGen shared an update with the community regarding the Vamorolone trials and COVID-19.
This program is sponsored by ReveraGen Biopharma and has been partially funded by Parent Project Muscular Dystrophy.
|A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)|
OPEN LABEL EXTENSION
|Long-term Extension Study to Assess Vamorolone|
Paula Clemmons, MD Presents at the PPMD 2019 Annual Conference
Webinar: Vamorolone Clinical Trials in DuchenneOn January 30, 2019, ReveraGen joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the vamorolone drug development program for Duchenne, including results showing improved muscle function in completed clinical trials in 48 Duchenne boys, and a description of an ongoing clinical trial of 120 Duchenne boys that is accepting new patients at 30 sites internationally.
ReveraGen Presents at the PPMD 2018 Annual Conference
Webinar: Vamorolone (VBP15) Clinical Trials in DuchenneOn January 18, 2017, PPMD was joined by ReveraGen BioPharma for a webinar discussion on vamorolone (VBP15) clinical trials in Duchenne.